FDA denies marketing authorization for two RJR Vuse menthol ecigs

Following the same logic FDA used to deny marketing authorization of JTI Logic menthol e-cigarettes, FDA has denied authorization for RJR to sell menthol versions of its Vuse Vibe Tank Menthol 3.0% and the Vuse Ciro Cartridge Menthol 1.5% e-cigs.

While FDA does not post the Marketing Denial Orders, Center for Tobacco Products Director Brian King said in FDA’s press release announcing the decision, “The applications for these products did not present sufficient scientific evidence to show that the potential benefit to adult smokers outweighs the risks of youth initiation and use.”

This is the same logic outlines in FDA’s post-Brian King assessment that menthol e-cigs in general do not have public health benefit.

Given that e-cigarettes as consumer products do not help smokers quit cigarettes — with the most recent best evidence showing e-cigarettes reduce quitting of cigarettes, the reality is that there is no benefit to adults against which risks to youth have to be balanced.

Just as FDA updated its assessment of menthol in e-cigarettes, it is time for FDA to issue a formal analysis of e-cigarettes as consumer products and smoking cessation.

In the meantime, FDA needs to move quickly to clear the market of the remaining menthol e-cigarettes.


Published by Stanton Glantz

Stanton Glantz is a retired Professor of Medicine who served on the University of California San Francisco faculty for 45 years. He conducts research on tobacco and cannabis control and cardiovascular disease/

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: